Pharmaceuticals and Biotechnology

We actively advise many of the world’s largest pharmaceutical and biotechnology companies in important corporate transactions, as well as on precedent-setting antitrust, regulatory, and litigation and arbitration issues.

GlaxoSmithKline in Dismissal of Antitrust Suit

In March 2011, we represented GlaxoSmithKline in the successful dismissal on summary judgment of a complaint in Alameda County, California Superior Court by 17 retail pharmacies alleging a conspiracy to fix the prices of all branded pharmaceuticals in California at levels higher than Canadian prices.

Practices: Antitrust and Competition and Litigation 
Office: Washington

Crucell in Acquisition by Johnson & Johnson

We represented Crucell, a Dutch biopharmaceutical company, on U.S. securities, M&A, and tax matters in connection with its acquisition by Johnson & Johnson for approximately $2.4 billion. The deal involved a U.S./Dutch tender offer for the 82% of Crucell that Johnson & Johnson did not already own.

Practice: M&A, Capital Markets, and Tax
Office: London and New York

IMS Health Cleared to Acquire SDI Health

We represented leading U.S. healthcare data provider IMS Health in obtaining U.S. Federal Trade Commission clearance for its acquisition of SDI Health, a healthcare market insight and analytics organization.

Practices: Antitrust and Competition
Offices: Washington

Amgen Acquires Laboratório Químico Farmacêutico Bergamo

We represented Amgen, the world’s largest biotechnology company, in its acquisition of Laboratório Químico Farmacêutico Bergamo, a privately-held pharmaceutical company based in São Paulo, Brazil.

Practices: M&A, Arbitration, and Tax 
Offices: New York

Axcan Buyout of Eurand Receives Antitrust Clearance

We advised Axcan, a leading pharmaceutical company focused on the treatment of gastrointestinal disorders, on the antitrust aspects of its $583 million acquisition of Eurand, a global specialty pharmaceutical company.

Practice: Antitrust and Competition
Office: Washington

CFR Pharmaceuticals in Debut Equity Offering

We represented CFR Pharmaceuticals, a leading Latin American pharmaceutical company, and its principal shareholder in a $370 million debut public equity offering, comprising an offering of shares by special auction on the Santiago Stock Exchange and a Reg S/Rule 144A offering of shares, including in the form of ADSs, outside of Chile.

Practices: Capital Markets and Tax
Offices: Buenos Aires and New York

Key Capital Markets Transactions

Our lawyers were also active in capital markets transactions in this sector, including as counsel in:

• Sanofi-aventis’ first SEC-registered bond offering, issued in six tranches in an aggregate principal amount of $7 billion, and in its subsequent $1 billion offering.
• Teva Pharmaceuticals’ $5 billion aggregate principal amount notes offering.
• United Therapeutics’ $250 million convertible notes offering and related note hedge, warrant, and accelerated share repurchase programs.

Practices: Capital Markets, Environmental Law, Executive Compensation and ERISA, Intellectual Property, Litigation, and Tax
Offices: Paris, New York, and Washington